Report copyright - 209566Orig1s000 - Food and Drug Administration · Results from a phase 1 dose linearity study (study 11903) indicated that the pharmacokinetics of midazolam was dose-proportional
Please pass captcha verification before submit form
Please pass captcha verification before submit form